Sera Prognostics (NASDAQ:SERA – Get Free Report) and Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.
Analyst Recommendations
This is a summary of recent ratings and target prices for Sera Prognostics and Black Diamond Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sera Prognostics | 1 | 0 | 1 | 1 | 2.67 |
| Black Diamond Therapeutics | 1 | 2 | 7 | 0 | 2.60 |
Sera Prognostics presently has a consensus target price of $5.50, suggesting a potential upside of 170.94%. Black Diamond Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 428.85%. Given Black Diamond Therapeutics’ higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Sera Prognostics.
Insider and Institutional Ownership
54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Sera Prognostics and Black Diamond Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sera Prognostics | -47,475.72% | -46.71% | -34.06% |
| Black Diamond Therapeutics | N/A | -32.10% | -25.21% |
Risk and Volatility
Sera Prognostics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 3.32, suggesting that its stock price is 232% more volatile than the S&P 500.
Earnings & Valuation
This table compares Sera Prognostics and Black Diamond Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sera Prognostics | $70,000.00 | 1,144.02 | -$31.93 million | ($0.67) | -3.03 |
| Black Diamond Therapeutics | $70.00 million | 1.71 | $22.37 million | ($0.75) | -2.77 |
Black Diamond Therapeutics has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Black Diamond Therapeutics beats Sera Prognostics on 9 of the 14 factors compared between the two stocks.
About Sera Prognostics
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.
